Mineralys stock gains after drug shows sustained blood pressure cuts
Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade)
Mineralys Therapeutics Inc (MLYS) Q3 2026 Earnings Call Highlights: Strong Phase 3 Data and ...
Mineralys Therapeutics (MLYS) Publishes Lorundrostat CKD Data, Is The Stock Still A Bargain?
What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript
Mineralys Therapeutics Q3 2026 Earnings Call Transcript
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Kidney Trial Results Could Change The Case For Mineralys Therapeutics Stock
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
Mineralys Therapeutics Announces Phase 2 Explore-CKD Trial Met Its Primary Endpoint; Publishes Full Results In The Journal 'Kidney International'
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain?
UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.